Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Digoxin

FDA-approved product (injectable, injection), marketed as Digoxin, Digoxin Pediatric, Lanoxicaps and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Digoxin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Digitalis glycosides
FDA pharmacologic class
Cardiac Glycoside FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Digoxin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Digoxin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rhythm Control of AF in Patients With Acute Stroke

    NCT02285387 · start 2014-11

    Registered record
    Registry ID
    NCT02285387
    Conditions
    Atrial Fibrillation
    Interventions
    Rhythm control; Rate control
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-11
    Completion
    2019-08
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionRhythm control; Rate control
    PhaseNot applicable
    Registry statusUnknown

  • Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma

    NCT02212639 · start 2014-09

    Registered record
    Registry ID
    NCT02212639
    Conditions
    Kaposi' s Sarcoma; Classic Kaposi' s Sarcoma; Endemic Kaposi' s Sarcoma; Lymph Angio Proliferations
    Interventions
    digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-09
    Completion
    2019-09
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKaposi' s Sarcoma; Classic Kaposi' s Sarcoma; Endemic Kaposi' s Sarcoma; Lymph Angio Proliferations
    Interventiondigoxin
    PhasePhase 2
    Registry statusUnknown

  • Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

    NCT02132767 · start 2014-05

    Registered record
    Registry ID
    NCT02132767
    Conditions
    Postoperative Atrial Fibrillation
    Interventions
    Amiodarone; DC-cardioversion; Rate Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-05
    Completion
    2015-09
    Enrolment
    523

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Atrial Fibrillation
    InterventionAmiodarone; DC-cardioversion; Rate Control
    PhasePhase 3
    Registry statusCompleted

  • Remission From Stage D Heart Failure

    NCT01774656 · start 2013-01

    Registered record
    Registry ID
    NCT01774656
    Conditions
    Heart Failure NYHA Class III; Heart Failure NYHA Class IV
    Interventions
    Pharmacological Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-01
    Completion
    2017-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure NYHA Class III; Heart Failure NYHA Class IV
    InterventionPharmacological Treatment
    PhasePhase 4
    Registry statusUnknown

  • A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers

    NCT01701739 · start 2012-10

    Registered record
    Registry ID
    NCT01701739
    Conditions
    Healthy Volunteer
    Interventions
    aleglitazar; digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10
    Completion
    2013-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    Interventionaleglitazar; digoxin
    PhasePhase 1
    Registry statusCompleted

  • Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass

    NCT01443039 · start 2011-09

    Registered record
    Registry ID
    NCT01443039
    Conditions
    Obesity
    Interventions
    phenotypical approach
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2014-02
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    Interventionphenotypical approach
    PhasePhase 1
    Registry statusCompleted

  • Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

    NCT01056874 · start 2010-03

    Registered record
    Registry ID
    NCT01056874
    Conditions
    Healthy; HIV Infections
    Interventions
    Digoxin; Digoxin; Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; HIV Infections
    InterventionDigoxin; Digoxin; Maraviroc
    PhasePhase 1
    Registry statusCompleted

  • Totally Endoscopic Ablation of Atrial Fibrillation

    NCT00940056 · start 2009-11

    Registered record
    Registry ID
    NCT00940056
    Conditions
    Atrial Fibrillation
    Interventions
    Endoscopic ablation of AF; Rate control
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-11
    Completion
    2015-05
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionEndoscopic ablation of AF; Rate control
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Evaluate the Effect of Fimasartan on Pharmacokinetics, and the Safety of Digoxin in Healthy Male Volunteers

    NCT00991783 · start 2009-08

    Registered record
    Registry ID
    NCT00991783
    Conditions
    Essential Hypertension
    Interventions
    Digoxin + Fimasartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    2009-11
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionDigoxin + Fimasartan
    PhasePhase 1
    Registry statusCompleted

  • Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin

    NCT00860223 · start 2009-04

    Registered record
    Registry ID
    NCT00860223
    Conditions
    Healthy
    Interventions
    Digoxin; Neratinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2009-04
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDigoxin; Neratinib
    PhasePhase 1
    Registry statusCompleted

  • Catheter Ablation Versus Medical Rate Control for Atrial Fibrillation in Patients With Heart Failure

    NCT00878384 · start 2009-04

    Registered record
    Registry ID
    NCT00878384
    Conditions
    Atrial Fibrillation; Heart Failure
    Interventions
    Medication to control ventricular rate in AF; Catheter Ablation for Persistent Atrial Fibrillation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-04
    Completion
    2012-07
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Heart Failure
    InterventionMedication to control ventricular rate in AF; Catheter Ablation for Persistent Atrial Fibrillation
    PhaseNot applicable
    Registry statusCompleted

  • Digoxin Drug-Drug Interaction With Lurasidone HCl

    NCT01082289 · start 2008-09

    Registered record
    Registry ID
    NCT01082289
    Conditions
    Schizophrenia
    Interventions
    Lurasidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionLurasidone
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers

    NCT02183402 · start 2008-06

    Registered record
    Registry ID
    NCT02183402
    Conditions
    Healthy
    Interventions
    Digoxin; BI 1356
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDigoxin; BI 1356
    PhasePhase 1
    Registry statusCompleted

  • Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure

    NCT01699776 · start 2008-04

    Registered record
    Registry ID
    NCT01699776
    Conditions
    Cardiac Failure
    Interventions
    Ivabradine; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-04
    Completion
    2012-02
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Failure
    InterventionIvabradine; Digoxin
    PhasePhase 4
    Registry statusCompleted

  • Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone

    NCT00504413 · start 2007-07

    Registered record
    Registry ID
    NCT00504413
    Conditions
    Substance-Related Disorders
    Interventions
    midazolam(drug), digoxin (drug); Bupropion (drug); Methadone (drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2007-07
    Completion
    2011-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubstance-Related Disorders
    Interventionmidazolam(drug), digoxin (drug); Bupropion (drug); Methadone (drug)
    PhasePhase 1
    Registry statusUnknown